Main Menu

Our Work

Grifols' proposed acquisition of Talecris

For more information, download the case study

Provided analysis on behalf of Grifols in connection with its acquisition of Talecris, both companies involved in the manufacture and sale of plasma-derived therapies used to treat a range of medical conditions. Evaluated possible coordinated effects concerns and assessed the merger specificity of claimed efficiencies in analysis presented to the FTC. Subsequent to a second request, FTC approved the transaction after Grifols agreed to a consent decree with provisions to facilitate entry.

Jump to Page